#78Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Cannabis hyperemesis syndrome represents an increasingly prevalent clinical entity that clinicians must recognize, as the 2025 epidemiological data showing 4.4 cases per 100,000 ED visits suggests this condition will become more common as cannabis legalization expands access. Early identification of CHS is critical because the syndrome produces severe, potentially dehydrating symptoms that can mimic other acute abdominal and GI emergencies, thereby improving diagnostic efficiency and reducing unnecessary investigations. Recognition of this cannabis-related adverse effect is essential for patient counseling and harm reduction discussions, particularly as the potency of available cannabis products continues to increase.
Cannabis hyperemesis syndrome is an increasingly prevalent condition associated with chronic heavy cannabis use, presenting with cyclic episodes of severe nausea, vomiting, and abdominal pain that frequently necessitate emergency department evaluation, with recent epidemiological data documenting an incidence of 4.4 cases per 100,000 emergency visits. The condition typically develops in long-term users and follows a characteristic pattern of prodromal symptoms progressing to hyperemetic episodes, often accompanied by compulsive hot bathing that temporarily alleviates symptoms. Recognition of CHS is clinically important because standard antiemetic therapies frequently prove ineffective, and diagnosis may be delayed in patients who do not initially disclose cannabis use, leading to unnecessary diagnostic workup and prolonged suffering. The rising prevalence of CHS correlates with increased cannabis availability and potency in recent years, suggesting that clinicians should maintain heightened awareness when evaluating patients with recurrent nausea and vomiting of unclear etiology. Definitive treatment requires complete cannabis cessation, though symptom resolution can be gradual even after discontinuation, underscoring the importance of early recognition and intervention. Physicians should routinely screen for cannabis use patterns in patients presenting with cyclic vomiting and counsel chronic users about the potential development of this syndrome to facilitate early detection and prompt cessation.
“Cannabis hyperemesis syndrome is a legitimate clinical entity that we’re seeing more frequently, and I believe it’s directly correlated with the increased potency and daily consumption patterns we’re observing in my practice, though the underlying mechanism remains incompletely understood and warrants more rigorous research.”
🌿 Cannabis hyperemesis syndrome represents a genuine clinical entity increasingly encountered in emergency departments, particularly as cannabis potency and frequency of use have escalated, though the exact pathophysiological mechanism remains incompletely understood and may involve cannabinoid receptor dysregulation or altered gastric motility. The syndrome presents diagnostic challenges because symptoms can mimic other conditions such as cyclic vomiting syndrome, gastroparesis, or acute surgical pathology, and a thorough substance use history combined with the classic pattern of symptom relief with hot showers is often necessary to establish the diagnosis. Importantly, patients may not spontaneously disclose cannabis use or may minimize consumption frequency, and the condition appears dose-dependent and associated with higher potency products, though individual susceptibility varies considerably. Clinicians should maintain a high index of suspicion in patients with recurrent severe nausea and vomiting without clear alternative etiology, particularly those in regions with increased
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: